LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+31.06%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$950M
AUM Growth
+$950M
(+5.7%)
Cap. Flow
+$2.46M
Cap. Flow
% of AUM
0.26%
Top 10 Holdings %
Top 10 Hldgs %
52.34%
Holding
74
New
23
Increased
9
Reduced
10
Closed
20
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$51.8M |
| 2 |
Immunocore
IMCR
|
$32.5M |
| 3 |
Geron
GERN
|
$29.7M |
| 4 |
Celldex Therapeutics
CLDX
|
$27.3M |
| 5 |
Vera Therapeutics
VERA
|
$24.8M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$107M |
| 2 |
argenx
ARGX
|
$55.2M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$35.3M |
| 4 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$29.9M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$28.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
IDEAYA Biosciences
IDYA
$2.15B
| $65.8M | 5.33% | 1,500,000 -300,000 | -17% | -$13.2M |
|
|
2
Immunocore
IMCR
$1.62B
| $58.5M | 4.73% | 900,000 +500,000 | +125% | +$32.5M |
|
3
Immunovant
IMVT
$2.56B
| $57.4M | 4.64% | 1,775,000 +575,000 | +48% | +$18.6M |
|
4
Ocular Therapeutix
OCUL
$2.12B
| $52M | 4.21% | 5,811,436 +1,811,436 | +45% | +$16.2M |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $51.8M | 4.19% | +400,000 | New | +$51.8M |
|
6
Olema Pharmaceuticals
OLMA
$375M
| $49.6M | 4.02% | 4,383,875 | – | – |
|
7
Dyne Therapeutics
DYN
$1.92B
| $49.1M | 3.98% | 1,730,000 -150,000 | -8% | -$4.26M |
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $47M | 3.81% | 800,000 -150,000 | -16% | -$8.82M |
|
9
Rocket Pharmaceuticals
RCKT
$354M
| $35M | 2.83% | 1,300,000 +25,000 | +2% | +$674K |
|
|
SLN
10
Silence Therapeutics
SLN
$227M
| $31.1M | 2.52% | 1,476,061 +1,076,061 | +269% | +$22.7M |
|
11
Structure Therapeutics
GPCR
$1.11B
| $30.9M | 2.5% | 720,058 -350,000 | -33% | -$15M |
|
|
12
Geron
GERN
$893M
| $29.7M | 2.4% | +9,000,000 | New | +$29.7M |
|
|
13
Celldex Therapeutics
CLDX
$1.47B
| $27.3M | 2.21% | +650,000 | New | +$27.3M |
|
14
Enliven Therapeutics
ELVN
$1.2B
| $26.4M | 2.14% | 1,574,220 +1,267,144 | +413% | +$21.3M |
|
|
15
Vera Therapeutics
VERA
$1.38B
| $24.8M | 2.01% | +575,000 | New | +$24.8M |
|
16
Annexon
ANNX
$226M
| $21.9M | 1.77% | 3,050,000 -1,900,000 | -38% | -$13.6M |
|
17
Adverum Biotechnologies
ADVM
$64.6M
| $21.2M | 1.72% | +1,499,999 | New | +$21.2M |
|
18
Design Therapeutics
DSGN
$315M
| $20.3M | 1.64% | 5,032,501 | – | – |
|
19
Akero Therapeutics
AKRO
$3.74B
| $20.2M | 1.64% | 800,000 | – | – |
|
20
Astria Therapeutics
ATXS
$349M
| $17.5M | 1.42% | 1,244,960 +700,000 | +128% | +$9.85M |
|
|
CYBN
21
Cybin
CYBN
$176M
| $16.5M | 1.34% | +40,000,000 | New | +$16.5M |
|
22
Xencor
XNCR
$580M
| $14.4M | 1.16% | +650,000 | New | +$14.4M |
|
23
CG Oncology
CGON
$2.04B
| $13.2M | 1.07% | +300,000 | New | +$13.2M |
|
24
enGene Holdings
ENGN
$236M
| $12.9M | 1.04% | +800,000 | New | +$12.9M |
|
25
Kyverna Therapeutics
KYTX
$160M
| $12.4M | 1.01% | +500,000 | New | +$12.4M |
|